Advertisement

Topics

Immupharma Plc IMM Financial and Strategic SWOT Analysis Review [Report Updated: 25072017] Prices from USD $125

07:30 EDT 24 Aug 2017 | BioPortfolio Reports

Immupharma Plc IMM Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description A detailed description of the company's operations and business divisions.
Corporate strategy Analyst's summarization of the company's business strategy.
SWOT Analysis A detailed analysis of the company's strengths, weakness, opportunities and threats.
Company history Progression of key events associated with the company.
Major products and services A list of major products, services and brands of the company.
Key competitors A list of key competitors to the company.
Key employees A list of the key executives of the company.
Executive biographies A brief summary of the executives' employment history.
Key operational heads A list of personnel heading key departments/functions.
Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.
Key manufacturing facilities A list of key manufacturing facilities of the company.
Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semiannual financial statements published by the company for 5 interims history.

Highlights

ImmuPharma Plc ImmuPharma develops novel drugs for the treatment of serious medical conditions with unmet medical need. ImmuPharma has five drugs in development stage towards the treatment of lupus, cancer, moderate to severe pain, highly resistant hospitalacquired infections such as methicillinresistant staphylococcus aureus infection and inflammatory disorders including rheumatoid arthritis and asthma. The company's product pipeline comprises Lupuzor, for the treatment of Lupus; IPP204106, for the treatment of cancer; IPP102199, for the treatment of moderate and severe pain, IPP203101, for the treatment of highly resistant, hospitalacquired infections, such as MRSA; and IPP201007, for the treatment of inflammatory and allergic disorders. It has operations in France and Switzerland. ImmuPharma is headquartered in England, the UK.

Immupharma Plc Key Recent Developments

Sep 30,2016: ImmuPharma: Interim Results Announcement for the six months ended 30 June 2016
May 04,2016: ImmuPharma Announces Preliminary Results For The Year Ended 31 December 2015

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Original Article: Immupharma Plc IMM Financial and Strategic SWOT Analysis Review [Report Updated: 25072017] Prices from USD $125

NEXT ARTICLE

More From BioPortfolio on "Immupharma Plc IMM Financial and Strategic SWOT Analysis Review [Report Updated: 25072017] Prices from USD $125"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Rheumatology
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Anesthesiology
An anesthesiologist (US English) or anaesthetist (British English) is a physician trained in anesthesia and perioperative medicine. Anesthesiologists are physicians who provide medical care to patients in a wide variety of (usually acute) situations. ...